Nplate Review Shows Struggle For Early Implementation Of REMS
This article was originally published in Pharmaceutical Approvals Monthly
Review deadline for Amgen’s romiplostim came only one month after REMS authority went into effect. Back and forth on risk management program shows agency desire for specific examples. Amgen cites need for guidance from FDA
You may also be interested in...
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.
Amgen and GSK are competing head-to-head in a new market for a rare blood disorder. The market size is small, but the commercial implications are huge: how will the new regulatory tools imposed by FDA affect competition in the real world?
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.